Are phosphodiesterase Type 5 inhibitors potential therapies for Alzheimer's disease and related dementias?

Danielle Newby

doi:10.1093/braincomms/fcac260

Are phosphodiesterase Type 5 inhibitors potential therapies for Alzheimer's disease and related dementias?

Brain Commun. 2022 Oct 11;4(5):fcac260. doi: 10.1093/braincomms/fcac260. eCollection 2022.

Author

Danielle Newby¹

Affiliation

¹ Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Centre for Statistics in Medicine, University of Oxford, Oxford, UK.

Abstract

This scientific commentary refers to 'No association between initiation of phosphodiesterase-5 inhibitors and risk of incident Alzheimer's disease and related dementia: results from the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study' by Desai et al. (https://doi.org/10.1093/braincomms/fcac247).